A DNA aptamer with high affinity and specificity for molecular recognition and targeting therapy of gastric cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Cao, Hong Yong ^a,b   Yuan, Ai Hua ^a   Chen, Wei ^a   Shi, Xue Song ^a   Miao, Yi ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

DNA aptamer; Gastric cancer; In vivo imaging; Live cell SELEX; Molecular probe

Indexed keywords

APTAMER; CY APT 20; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CANCER CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; FEASIBILITY STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR PROBE; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; TUMOR LOCALIZATION; ANIMAL; COMBINATORIAL CHEMISTRY; DIAGNOSTIC USE; DISEASE MODEL; DRUG SCREENING; MOLECULAR IMAGING; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; SELEX APTAMER TECHNIQUE; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929942514     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-699     Document Type: Article

References (31)

1. Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M: A review on biomarkers for prediction of treatment outcome in gastric cancer. Anticancer Res 2013, 33(4):1257-1266.
2. Durães C, Almeida GM, Seruca R, Oliveira C, Carneiro F: Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch 2014, 464:367-378.
3. Takahashi T, Saikawa Y, Kitagawa Y: Gastric cancer: current status of diagnosis and treatment. Cancer 2013, 5(1):48-63.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
5. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr.
6. Jang BG, Kim WH: Molecular pathology of gastric carcinoma. Pathobiol 2011, 78(6):302-310.
7. Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y, Oue N: Molecular pathology of gastric cancer: research and practice. Pathol Res Pract 2011, 207(10):608-612.
8. Ding SZ, Goldberg JB, Hatakeyama M: Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol 2010, 6(5):851-862.
9. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N: Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 2014, 50(7):1330-1344.
10. Diamandis EP: Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010, 102(19):1462-1467.
11. Almendro V, Marusyk A, Polyak K: Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013, 24(8):277-302.
12. Kern SE: Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 2012, 72(23):6097-6101.
13. Pavlou MP, Diamandis EP, Blasutig IM: The long journey of cancer biomarkers from the bench to the clinic. Clin Chem 2013, 59(1):147-157.
14. Lassalle HP, Marchal S, Guillemin F, Reinhard A, Bezdetnaya L: Aptamers as remarkable diagnostic and therapeutic agents in cancer treatment. Curr Drug Metab 2012, 13(8):1130-1144.
15. Radom F, Jurek PM, Mazurek MP, Otlewski J, Jelen F: Aptamers: molecules of great potential. Biotechnol Adv 2013, 31(8):1260-1274.
16. Tuerk C, Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249(4968):505-510.
17. Stoltenburg R, Reinemann C, Strehlitz B: SELEX-a (r) evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 2007, 24(4):381-403.
18. Hermann T, Patel DJ: Adaptive recognition by nucleic acid aptamers. Science 2000, 287(5454):820-825.
19. Sefah K, Shangguan D, Xiong X, O'Donoghue MB, Tan W: Development of DNA aptamers using Cell-SELEX. Nat Protoc 2010, 5(6):1169-1185.
20. Zhu G, Ye M, Donovan MJ, Song E, Zhao Z, Tan W: Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem Commun (Camb) 2012, 48(85):10472-10480.
21. Cerchia L, de Franciscis V: Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol 2010, 28(10):517-525.
22. Zhang Y, Chen Y, Han D, Ocsoy I, Tan W: Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis 2010, 2(5):907-918.
23. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, Sefah K, Yang CJ, Tan W: Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 2006, 103(32):11838-11843.
24. Sefah K, Tang ZW, Shangguan DH, Chen H, Lopez-Colon D, Li Y, Parekh P, Martin J, Meng L, Phillips JA, Kim YM, Tan WH: Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 2009, 23(2):235-244.
25. Zhang K, Sefah K, Tang L, Zhao Z, Zhu G, Ye M, Sun W, Goodison S, Tan W: Novel aptamer developed for breast cancer cell internalization. ChemMedChem 2012, 7(1):79-84.
26. Kunii T, Ogura S, Mie M, Kobatake E: Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX. Analyst 2011, 136(7):1310-1312.
27. Sefah K, Meng L, Lopez-Colon D, Jimenez E, Liu C, Tan W: DNA aptamers as molecular probes for colorectal cancer study. PLoS One 2010, 5(12):e14269.
28. Sefah K, Bae KM, Phillips JA, Siemann DW, Su Z, McClellan S, Vieweg J, Tan W: Cell-based selection provides novel molecular probes for cancer stem cells. Int J Cancer 2013, 132(11):2578-2588.
29. Zueva E, Rubio LI, Ducongé F, Tavitian B: Metastasis-focused cell-based SELEX generates aptamers inhibiting cell migration and invasion. Int J Cancer 2011, 128(4):797-804.
30. Hu M, Zhang K: The application of aptamers in cancer research: an up-to-date review. Future Oncol 2013, 9(3):369-376.
31. Xing H, Hwang K, Li J, Torabi SF, Lu Y: DNA aptamer technology for personalized medicine. Curr Opin Chem Eng 2014, 5(4):79-87.